Treatment-related adverse events
| Adverse event . | All HSCT (N = 28) . | Mild-moderate-severe VOD/SOS (n = 11) . | Very severe VOD/SOS (n = 17) . |
|---|---|---|---|
| Hypotension, n (%) | 3 (11) | 0 | 3 (18) |
| Lower gastrointestinal hemorrhage, n (%) | 1 (4) | 0 | 1 (6) |
| Epistaxis, n (%) | 5 (18) | 1 (9) | 4 (24) |
| Grade III/IV pulmonary hemorrhage, n (%) | 1 (4) | 0 | 1 (6) |
| Grade III/IV upper gastrointestinal hemorrhage, n (%) | 1 (4) | 0 | 1 (6) |
| Hematuria, n (%) | 12 (43) | 3 (27) | 9 (53) |
| Adverse event . | All HSCT (N = 28) . | Mild-moderate-severe VOD/SOS (n = 11) . | Very severe VOD/SOS (n = 17) . |
|---|---|---|---|
| Hypotension, n (%) | 3 (11) | 0 | 3 (18) |
| Lower gastrointestinal hemorrhage, n (%) | 1 (4) | 0 | 1 (6) |
| Epistaxis, n (%) | 5 (18) | 1 (9) | 4 (24) |
| Grade III/IV pulmonary hemorrhage, n (%) | 1 (4) | 0 | 1 (6) |
| Grade III/IV upper gastrointestinal hemorrhage, n (%) | 1 (4) | 0 | 1 (6) |
| Hematuria, n (%) | 12 (43) | 3 (27) | 9 (53) |